MLP Care 2Q24 Financial Results

We attended MLP Sağlık's analyst meeting to assess the company's 2Q24 financial results, current operations, and future outlook. We maintain our "Buy" recommendation for MPARK with a target price of TL 385 and continue to keep it in our Model Portfolio.